Compare Stocks: TXMD, CGTX, MNOV, and ICCC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGTX Cognition Therapeutics	$1.04 -1.9%	$1.00	$0.55 ▼ $2.05	$98.90M	1.79	348,518 shs	336,211 shs
ICCC ImmuCell	$9.95 -0.3%	$10.46	$4.52 ▼ $12.10	$90.37M	0.54	16,152 shs	10,036 shs
MNOV MediciNova	$3.32 -3.8%	$1.54	$1.17 ▼ $3.90	$163.41M	0.63	502,324 shs	1.63 million shs
TXMD TherapeuticsMD	$2.19 +0.5%	$2.10	$0.99 ▼ $2.95	$25.35M	0.65	32,175 shs	7,962 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGTX Cognition Therapeutics	0.00%	+5.82%	+8.71%	-28.28%	-29.25%
ICCC ImmuCell	0.00%	+1.02%	-1.39%	+4.85%	+76.11%
MNOV MediciNova	0.00%	+83.43%	+142.34%	+151.52%	+172.13%
TXMD TherapeuticsMD	0.00%	+1.39%	+6.31%	+12.31%	+106.60%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGTX Cognition Therapeutics	$1.04 -1.9%	$1.00	$0.55 ▼ $2.05	$98.90M	1.79	348,518 shs	336,211 shs
ICCC ImmuCell	$9.95 -0.3%	$10.46	$4.52 ▼ $12.10	$90.37M	0.54	16,152 shs	10,036 shs
MNOV MediciNova	$3.32 -3.8%	$1.54	$1.17 ▼ $3.90	$163.41M	0.63	502,324 shs	1.63 million shs
TXMD TherapeuticsMD	$2.19 +0.5%	$2.10	$0.99 ▼ $2.95	$25.35M	0.65	32,175 shs	7,962 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGTX Cognition Therapeutics	0.00%	+5.82%	+8.71%	-28.28%	-29.25%
ICCC ImmuCell	0.00%	+1.02%	-1.39%	+4.85%	+76.11%
MNOV MediciNova	0.00%	+83.43%	+142.34%	+151.52%	+172.13%
TXMD TherapeuticsMD	0.00%	+1.39%	+6.31%	+12.31%	+106.60%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGTX Cognition Therapeutics	2.50	Moderate Buy	$3.33	220.51% Upside
ICCC ImmuCell	2.00	Hold	N/A	N/A
MNOV MediciNova	2.86	Moderate Buy	$7.75	133.43% Upside
TXMD TherapeuticsMD	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest TXMD, CGTX, MNOV, and ICCC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/17/2026	MNOV MediciNova	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$6.00
9/17/2026	MNOV MediciNova	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/2/2026	MNOV MediciNova	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/26/2026	TXMD TherapeuticsMD	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D-)
8/18/2026	ICCC ImmuCell	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Hold (C-)
8/13/2026	CGTX Cognition Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/12/2026	TXMD TherapeuticsMD	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Sell (D+)
8/11/2026	MNOV MediciNova	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/2/2026	ICCC ImmuCell	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/2/2026	TXMD TherapeuticsMD	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/24/2026	CGTX Cognition Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGTX Cognition Therapeutics	N/A	N/A	N/A	N/A	$0.39 per share	N/A
ICCC ImmuCell	$27.64M	3.27	$0.19 per share	51.61	$2.99 per share	3.33
MNOV MediciNova	$410K	398.56	N/A	N/A	$0.85 per share	3.91
TXMD TherapeuticsMD	$3.02M	8.39	$0.05 per share	46.94	$2.32 per share	0.94

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGTX Cognition Therapeutics	-$23.49M	-$0.17	N/A	N/A	N/A	N/A	-50.17%	-40.22%	11/5/2026 (Estimated)
ICCC ImmuCell	-$1.04M	$0.08	124.39	N/A	N/A	2.57%	2.69%	1.76%	11/12/2026 (Estimated)
MNOV MediciNova	-$12M	-$0.21	N/A	N/A	N/A	-1,168.70%	-26.51%	-24.39%	11/12/2026 (Estimated)
TXMD TherapeuticsMD	-$570K	$0.02	109.50	N/A	N/A	-6.64%	-1.09%	-0.78%	11/17/2026 (Estimated)

Latest TXMD, CGTX, MNOV, and ICCC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	ICCC ImmuCell	$0.05	$0.20	+$0.15	$0.20	$5.40 million	$7.19 million
8/13/2026	Q2 2026	MNOV MediciNova	-$0.0633	-$0.05	+$0.0133	-$0.05	$0.08 million	$0.46 million
8/11/2026	Q2 2026	TXMD TherapeuticsMD	-$6.1250	$0.01	+$6.1350	$0.01	$19.77 million	$0.87 million
8/6/2026	Q2 2026	CGTX Cognition Therapeutics	-$0.0633	-$0.04	+$0.0233	-$0.04	$5.00 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGTX Cognition Therapeutics	N/A	N/A	N/A	N/A	N/A
ICCC ImmuCell	N/A	N/A	N/A	N/A	N/A
MNOV MediciNova	N/A	N/A	N/A	N/A	N/A
TXMD TherapeuticsMD	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGTX Cognition Therapeutics	N/A	7.03	7.03
ICCC ImmuCell	0.22	4.75	2.71
MNOV MediciNova	N/A	8.75	8.75
TXMD TherapeuticsMD	N/A	3.22	3.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGTX Cognition Therapeutics	43.35%
ICCC ImmuCell	13.47%
MNOV MediciNova	9.90%
TXMD TherapeuticsMD	30.74%

Insider Ownership

Company	Insider Ownership
CGTX Cognition Therapeutics	11.11%
ICCC ImmuCell	5.70%
MNOV MediciNova	14.00%
TXMD TherapeuticsMD	1.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGTX Cognition Therapeutics	14	95.09 million	84.53 million	Not Optionable
ICCC ImmuCell	73	9.08 million	8.56 million	Not Optionable
MNOV MediciNova	6	49.22 million	42.33 million	Optionable
TXMD TherapeuticsMD	420	11.57 million	11.38 million	Optionable

TXMD, CGTX, MNOV, and ICCC Headlines

Recent News About These Companies

Critical Contrast: Nutriband (NASDAQ:NTRB) versus TherapeuticsMD (NASDAQ:TXMD)

September 16, 2026 | americanbankingnews.com

TherapeuticsMD Inc. stock underperforms Thursday when compared to competitors despite daily gains

June 5, 2026 | marketwatch.com

TherapeuticsMD Reports Quarterly Profit, Evaluates Strategic Alternatives

May 12, 2026 | tipranks.com

TherapeuticsMD Announces First Quarter 2026 Financial Results

May 12, 2026 | businesswire.com

TherapeuticsMD Inc. stock outperforms competitors on strong trading day

April 6, 2026 | marketwatch.com

TherapeuticsMD Narrows 2025 Loss, Advances Royalty Strategy

April 2, 2026 | theglobeandmail.com

TherapeuticsMD Explains Brief Delay In Annual Filing

April 1, 2026 | tipranks.com

TherapeuticsMD Announces Full Year 2025 Financial Results

March 30, 2026 | finance.yahoo.com

TherapeuticsMD Announces Full Year 2025 Financial Results

March 30, 2026 | businesswire.com

TherapeuticsMD (NASDAQ:TXMD) Director Tommy Thompson Buys 8,400 Shares

December 30, 2025 | insidertrades.com

TherapeuticsMD approves key proposals at annual meeting

December 16, 2025 | msn.com

TherapeuticsMD: Q3 Earnings Snapshot

November 13, 2025 | timesunion.comT

TherapeuticsMD Reports Q3 2025 Financial Results

November 13, 2025 | msn.com

TherapeuticsMD Announces Third Quarter 2025 Financial Results

November 12, 2025 | businesswire.com

TherapeuticsMD Reports Q2 2025 Financial Results

August 12, 2025 | msn.com

TherapeuticsMD: Q2 Earnings Snapshot

August 12, 2025 | finance.yahoo.com

TherapeuticsMD Announces Second Quarter 2025 Financial Results

August 12, 2025 | businesswire.com

TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors despite daily gains

July 16, 2025 | marketwatch.com

Marlan D. Walker - TXMD | TherapeuticsMD Inc. - Wall Street Journal

June 29, 2025 | wsj.com

Mayne Pharma Files Legal Complaint Against TherapeuticsMD

June 1, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TXMD, CGTX, MNOV, and ICCC Company Descriptions

Cognition Therapeutics NASDAQ:CGTX

$1.04 -0.02 (-1.89%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.04 0.00 (-0.10%)

As of 09/18/2026 07:58 PM Eastern

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

ImmuCell NASDAQ:ICCC

$9.95 -0.03 (-0.30%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$9.90 -0.04 (-0.45%)

As of 09/18/2026 07:30 PM Eastern

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

MediciNova NASDAQ:MNOV

$3.32 -0.13 (-3.77%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$3.33 +0.01 (+0.27%)

As of 09/18/2026 07:59 PM Eastern

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

TherapeuticsMD NASDAQ:TXMD

$2.19 +0.01 (+0.46%)

As of 09/18/2026 04:00 PM Eastern

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TXMD, CGTX, MNOV, and ICCC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TXMD, CGTX, MNOV, and ICCC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TXMD, CGTX, MNOV, and ICCC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TXMD, CGTX, MNOV, and ICCC Company Descriptions

Cognition Therapeutics NASDAQ:CGTX

ImmuCell NASDAQ:ICCC

MediciNova NASDAQ:MNOV

TherapeuticsMD NASDAQ:TXMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TXMD, CGTX, MNOV, and ICCC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TXMD, CGTX, MNOV, and ICCC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TXMD, CGTX, MNOV, and ICCC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TXMD, CGTX, MNOV, and ICCC Company Descriptions

Cognition Therapeutics NASDAQ:CGTX

ImmuCell NASDAQ:ICCC

MediciNova NASDAQ:MNOV

TherapeuticsMD NASDAQ:TXMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools